| MeSH term | MeSH ID | Detail |
|---|---|---|
| Leukemia | D007938 | 74 associated lipids |
| Carcinoma, Hepatocellular | D006528 | 140 associated lipids |
| Liver Cirrhosis | D008103 | 67 associated lipids |
| Hematoma | D006406 | 5 associated lipids |
| Demyelinating Diseases | D003711 | 15 associated lipids |
| Peripheral Nervous System Diseases | D010523 | 33 associated lipids |
| Lymphoproliferative Disorders | D008232 | 7 associated lipids |
| Crohn Disease | D003424 | 12 associated lipids |
| Osteoarthritis, Knee | D020370 | 13 associated lipids |
| Arthritis, Infectious | D001170 | 8 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Djamali A et al. | Nox2 is a mediator of chronic CsA nephrotoxicity. | 2012 | Am. J. Transplant. | pmid:22568654 |
| Cavadas PC et al. | Bilateral trans-humeral arm transplantation: result at 2 years. | 2011 | Am. J. Transplant. | pmid:21521475 |
| Egli A et al. | Renal failure five years after lung transplantation due to polyomavirus BK-associated nephropathy. | 2010 | Am. J. Transplant. | pmid:20840474 |
| Zafrani L et al. | Incidence, risk factors and clinical consequences of neutropenia following kidney transplantation: a retrospective study. | 2009 | Am. J. Transplant. | pmid:19538494 |
| Touzot M et al. | Renal transplantation in HIV-infected patients: the Paris experience. | 2010 | Am. J. Transplant. | pmid:20840478 |
| Krämer BK et al. | Tacrolimus once daily (ADVAGRAF) versus twice daily (PROGRAF) in de novo renal transplantation: a randomized phase III study. | 2010 | Am. J. Transplant. | pmid:20840480 |
| TruneÄka P et al. | Once-daily prolonged-release tacrolimus (ADVAGRAF) versus twice-daily tacrolimus (PROGRAF) in liver transplantation. | 2010 | Am. J. Transplant. | pmid:20840481 |
| Wang Q et al. | Biodegradable microsphere-loaded tacrolimus enhanced the effect on mice islet allograft and reduced the adverse effect on insulin secretion. | 2004 | Am. J. Transplant. | pmid:15084166 |
| Schubert M et al. | Pharmacokinetics of sirolimus and tacrolimus in pediatric transplant patients. | 2004 | Am. J. Transplant. | pmid:15084173 |
| Borrows R et al. | Steroid sparing with tacrolimus and mycophenolate mofetil in renal transplantation. | 2004 | Am. J. Transplant. | pmid:15476485 |
| Silva HT et al. | Planned randomized conversion from tacrolimus to sirolimus-based immunosuppressive regimen in de novo kidney transplant recipients. | 2013 | Am. J. Transplant. | pmid:24266969 |
| Ricciardelli I et al. | Rapid generation of EBV-specific cytotoxic T lymphocytes resistant to calcineurin inhibitors for adoptive immunotherapy. | 2013 | Am. J. Transplant. | pmid:24266973 |
| Budde K et al. | Sotrastaurin, a novel small molecule inhibiting protein kinase C: first clinical results in renal-transplant recipients. | 2010 | Am. J. Transplant. | pmid:20121745 |
| Damon C et al. | Predictive Modeling of Tacrolimus Dose Requirement Based on High-Throughput Genetic Screening. | 2017 | Am. J. Transplant. | pmid:27597269 |
| McKenna G and Trotter JF | Does early (CNI) conversion lead to eternal (renal) salvation? | 2010 | Am. J. Transplant. | pmid:20928938 |
| Hanto DW et al. | Intraoperative administration of inhaled carbon monoxide reduces delayed graft function in kidney allografts in Swine. | 2010 | Am. J. Transplant. | pmid:20977633 |
| Al-Massarani G et al. | Impact of immunosuppressive treatment on endothelial biomarkers after kidney transplantation. | 2008 | Am. J. Transplant. | pmid:18925903 |
| Frassetto LA and Benet LZ | Pharmacogenomics and transplantation: where are we? | 2004 | Am. J. Transplant. | pmid:15147415 |
| MacPhee IA et al. | The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. | 2004 | Am. J. Transplant. | pmid:15147425 |
| Artz MA et al. | Conversion from cyclosporine to tacrolimus improves quality-of-life indices, renal graft function and cardiovascular risk profile. | 2004 | Am. J. Transplant. | pmid:15147428 |
| Hesselink DA et al. | Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. | 2005 | Am. J. Transplant. | pmid:15816878 |
| Byrne GW et al. | Warfarin or low-molecular-weight heparin therapy does not prolong pig-to-primate cardiac xenograft function. | 2005 | Am. J. Transplant. | pmid:15816881 |
| Schold JD | The burden of proof in the design of early phase clinical trials. | 2013 | Am. J. Transplant. | pmid:23802723 |
| Willicombe M et al. | Outcome of patients with preformed donor-specific antibodies following alemtuzumab induction and tacrolimus monotherapy. | 2011 | Am. J. Transplant. | pmid:21299828 |
| Muthusamy AS et al. | Alemtuzumab induction and steroid-free maintenance immunosuppression in pancreas transplantation. | 2008 | Am. J. Transplant. | pmid:18828772 |
| Srinivas TR et al. | The noninferiority trial: don't don't do it. | 2010 | Am. J. Transplant. | pmid:21087412 |
| Vanrenterghem Y et al. | Minimization of immunosuppressive therapy after renal transplantation: results of a randomized controlled trial. | 2005 | Am. J. Transplant. | pmid:15636615 |
| Sindhi R et al. | Enhanced donor-specific alloreactivity occurs independently of immunosuppression in children with early liver rejection. | 2005 | Am. J. Transplant. | pmid:15636616 |
| Shergill AK et al. | Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. | 2005 | Am. J. Transplant. | pmid:15636619 |
| Tydén G et al. | ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab. | 2005 | Am. J. Transplant. | pmid:15636623 |
| RodrÃguez-Perálvarez M et al. | Tacrolimus exposure after liver transplantation in randomized controlled trials: too much for too long. | 2013 | Am. J. Transplant. | pmid:23621166 |
| Vanhove T et al. | Determinants of the Magnitude of Interaction Between Tacrolimus and Voriconazole/Posaconazole in Solid Organ Recipients. | 2017 | Am. J. Transplant. | pmid:28224698 |
| Bhorade SM et al. | Comparison of three tacrolimus-based immunosuppressive regimens in lung transplantation. | 2003 | Am. J. Transplant. | pmid:14629288 |
| Madeleine MM et al. | HPV-related cancers after solid organ transplantation in the United States. | 2013 | Am. J. Transplant. | pmid:24119294 |
| Pondrom S | The AJT report. | 2008 | Am. J. Transplant. | pmid:18324976 |
| Shihab F et al. | Association of Clinical Events With Everolimus Exposure in Kidney Transplant Patients Receiving Low Doses of Tacrolimus. | 2017 | Am. J. Transplant. | pmid:28141897 |
| O'Connell PJ et al. | Multicenter Australian trial of islet transplantation: improving accessibility and outcomes. | 2013 | Am. J. Transplant. | pmid:23668890 |
| RodrÃguez-Perálvarez M et al. | Tacrolimus trough levels, rejection and renal impairment in liver transplantation: a systematic review and meta-analysis. | 2012 | Am. J. Transplant. | pmid:22703529 |
| Budde K | How to use mTOR inhibitors? The search goes on. | 2011 | Am. J. Transplant. | pmid:21668636 |
| Chen G et al. | Anti-CD45RB monoclonal antibody prolongs renal allograft survival in cynomolgus monkeys. | 2007 | Am. J. Transplant. | pmid:17227555 |
| Servais A et al. | Interstitial fibrosis evolution on early sequential screening renal allograft biopsies using quantitative image analysis. | 2011 | Am. J. Transplant. | pmid:21672152 |
| Senior PA et al. | Changes in renal function after clinical islet transplantation: four-year observational study. | 2007 | Am. J. Transplant. | pmid:17227560 |
| Ryan CM and Swanson DP | clinical research, innovative practice and IRB review: identifying and respecting boundaries. | 2007 | Am. J. Transplant. | pmid:17331113 |
| Nijhoff MF et al. | Glycemic Stability Through Islet-After-Kidney Transplantation Using an Alemtuzumab-Based Induction Regimen and Long-Term Triple-Maintenance Immunosuppression. | 2016 | Am. J. Transplant. | pmid:26288226 |
| Lefaucheur C et al. | Renal histopathological lesions after lung transplantation in patients with cystic fibrosis. | 2008 | Am. J. Transplant. | pmid:18671673 |
| Triñanes J et al. | Deciphering Tacrolimus-Induced Toxicity in Pancreatic β Cells. | 2017 | Am. J. Transplant. | pmid:28432716 |
| Haufroid V et al. | CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: guidelines from an experimental study. | 2006 | Am. J. Transplant. | pmid:17049058 |
| Pallet N et al. | Long-Term Clinical Impact of Adaptation of Initial Tacrolimus Dosing to CYP3A5 Genotype. | 2016 | Am. J. Transplant. | pmid:26990694 |
| Miller LW | Cardiovascular toxicities of immunosuppressive agents. | 2002 | Am. J. Transplant. | pmid:12392286 |
| Chhabra D et al. | Impact of calcineurin-inhibitor conversion to mTOR inhibitor on renal allograft function in a prednisone-free regimen. | 2013 | Am. J. Transplant. | pmid:24007570 |